speb/financial-data huggingface dataset:
NATCAPSUQ.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: -49768000.00
NATCAPSUQ.NS cash_flow (annual, 2026-03-31) — Net Income From Continuing Operations: -279202000.00
NATCAPSUQ.NS income_statement (annual, 2026-03-31) — Net Income Including Noncontrolling Interests: -246634000.00
NATCAPSUQ.NS income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: -49768000.00
NATCAPSUQ.NS cash_flow (annual, 2026-03-31) — Net Intangibles Purchase And Sale: 0.00
NATCAPSUQ.NS income_statement (annual, 2026-03-31) — Net Interest Income: -108582000.00
NATCAPSUQ.NS income_statement (quarterly, 2026-03-31) — Net Interest Income: -28898000.00
NATCAPSUQ.NS cash_flow (annual, 2026-03-31) — Net Investment Purchase And Sale: 0.00
NATCAPSUQ.NS cash_flow (annual, 2026-03-31) — Net Issuance Payments Of Debt: 105359000.00
NATCAPSUQ.NS cash_flow (annual, 2026-03-31) — Net Long Term Debt Issuance: 105359000.00
NATCAPSUQ.NS income_statement (annual, 2026-03-31) — Net Non Operating Interest Income Expense: -108582000.00
NATCAPSUQ.NS income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -28898000.00
NATCAPSUQ.NS cash_flow (annual, 2026-03-31) — Net Other Financing Charges: 1000.00
NATCAPSUQ.NS cash_flow (annual, 2026-03-31) — Net Other Investing Changes: 1000.00
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Net PPE: 2780168000.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Net PPE: 2780168000.00
NATCAPSUQ.NS cash_flow (annual, 2026-03-31) — Net PPE Purchase And Sale: -115303000.00
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Net Tangible Assets: 2216355000.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 2216355000.00
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Assets: 26316000.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Assets: 26316000.00
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Liabilities: 0.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 0.00
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 12613000.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 12613000.00
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Non Current Prepaid Assets: 25682000.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Non Current Prepaid Assets: 25682000.00
NATCAPSUQ.NS income_statement (annual, 2026-03-31) — Normalized EBITDA: 7624000.00
NATCAPSUQ.NS income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 20946000.00
NATCAPSUQ.NS income_statement (annual, 2026-03-31) — Normalized Income: -241417798.93
NATCAPSUQ.NS income_statement (quarterly, 2026-03-31) — Normalized Income: -49768000.00
NATCAPSUQ.NS cash_flow (annual, 2026-03-31) — Operating Cash Flow: 109170000.00
NATCAPSUQ.NS income_statement (annual, 2026-03-31) — Operating Income: -191289000.00
NATCAPSUQ.NS income_statement (quarterly, 2026-03-31) — Operating Income: -29505000.00
NATCAPSUQ.NS income_statement (annual, 2026-03-31) — Operating Revenue: 1830881000.00
NATCAPSUQ.NS income_statement (quarterly, 2026-03-31) — Operating Revenue: 584533000.00
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Ordinary Shares Number: 10386154.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 10386154.00
NATCAPSUQ.NS cash_flow (annual, 2026-03-31) — Other Cash Adjustment Outside Changein Cash: -1000.00
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Other Current Assets: 2237000.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 2237000.00
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Other Current Liabilities: 71752000.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 71752000.00
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Other Equity Interest: 12125000.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Other Equity Interest: 12125000.00
NATCAPSUQ.NS cash_flow (annual, 2026-03-31) — Other Non Cash Items: 101839000.00
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Other Non Current Assets: -2000.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: -2000.00
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Other Non Current Liabilities: -2000.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Liabilities: -2000.00
NATCAPSUQ.NS income_statement (annual, 2026-03-31) — Other Non Operating Income Expenses: 9667000.00
NATCAPSUQ.NS income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: 7640000.00
NATCAPSUQ.NS income_statement (annual, 2026-03-31) — Other Operating Expenses: 333978000.00
NATCAPSUQ.NS income_statement (quarterly, 2026-03-31) — Other Operating Expenses: 161600000.00
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Other Payable: 68463000.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Other Payable: 68463000.00
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Other Properties: 31196000.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Other Properties: 31196000.00
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Other Short Term Investments: 45549000.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 45549000.00
NATCAPSUQ.NS income_statement (annual, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
NATCAPSUQ.NS income_statement (quarterly, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Payables: 636404000.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Payables: 636404000.00
NATCAPSUQ.NS cash_flow (annual, 2026-03-31) — Pension And Employee Benefit Expense: -55000.00
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 461000.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 461000.00
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Preferred Stock: 466660000.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Preferred Stock: 466660000.00
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Preferred Stock Equity: 466660000.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Preferred Stock Equity: 466660000.00
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Prepaid Assets: 340714000.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Prepaid Assets: 340714000.00
NATCAPSUQ.NS income_statement (annual, 2026-03-31) — Pretax Income: -279202000.00
NATCAPSUQ.NS income_statement (quarterly, 2026-03-31) — Pretax Income: -50765000.00
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Properties: 0.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Properties: 0.00
NATCAPSUQ.NS cash_flow (annual, 2026-03-31) — Purchase Of Investment: 0.00
NATCAPSUQ.NS cash_flow (annual, 2026-03-31) — Purchase Of PPE: -115303000.00
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Raw Materials: 100452000.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Raw Materials: 100452000.00
NATCAPSUQ.NS income_statement (annual, 2026-03-31) — Reconciled Cost Of Revenue: 1074674000.00
NATCAPSUQ.NS income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 354829000.00
NATCAPSUQ.NS income_statement (annual, 2026-03-31) — Reconciled Depreciation: 171434000.00
NATCAPSUQ.NS income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 42813000.00
NATCAPSUQ.NS income_statement (annual, 2026-03-31) — Rent And Landing Fees: 0.00
NATCAPSUQ.NS income_statement (annual, 2026-03-31) — Rent Expense Supplemental: 0.00
NATCAPSUQ.NS cash_flow (annual, 2026-03-31) — Repayment Of Debt: 0.00
NATCAPSUQ.NS income_statement (annual, 2026-03-31) — Research And Development: 35726000.00
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Restricted Cash: 486000.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Restricted Cash: 486000.00
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Retained Earnings: 659697000.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Retained Earnings: 659697000.00
NATCAPSUQ.NS cash_flow (annual, 2026-03-31) — Sale Of Investment: 0.00
NATCAPSUQ.NS cash_flow (annual, 2026-03-31) — Sale Of PPE: 0.00
NATCAPSUQ.NS income_statement (annual, 2026-03-31) — Selling And Marketing Expense: 117428000.00
NATCAPSUQ.NS income_statement (annual, 2026-03-31) — Selling General And Administration: 147526000.00
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Share Issued: 10386154.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Share Issued: 10386154.00
NATCAPSUQ.NS income_statement (annual, 2026-03-31) — Special Income Charges: -5905000.00
NATCAPSUQ.NS income_statement (quarterly, 2026-03-31) — Special Income Charges: 0.00
NATCAPSUQ.NS cash_flow (annual, 2026-03-31) — Stock Based Compensation: 21851000.00
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Stockholders Equity: 2216355000.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 2216355000.00
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Tangible Book Value: 1749695000.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 1749695000.00
NATCAPSUQ.NS income_statement (annual, 2026-03-31) — Tax Effect Of Unusual Items: -688798.93
NATCAPSUQ.NS income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
NATCAPSUQ.NS income_statement (annual, 2026-03-31) — Tax Provision: -32568000.00
NATCAPSUQ.NS income_statement (quarterly, 2026-03-31) — Tax Provision: -997000.00
NATCAPSUQ.NS income_statement (annual, 2026-03-31) — Tax Rate For Calcs: 0.12
NATCAPSUQ.NS income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.02
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Taxes Receivable: 0.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Taxes Receivable: 0.00
NATCAPSUQ.NS cash_flow (annual, 2026-03-31) — Taxes Refund Paid: -36236000.00
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Total Assets: 4241578000.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Total Assets: 4241578000.00
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Total Capitalization: 2763584000.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 2763584000.00
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Total Debt: 1154780000.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Total Debt: 1154780000.00
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Total Equity Gross Minority Interest: 2347221000.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 2347221000.00
NATCAPSUQ.NS income_statement (annual, 2026-03-31) — Total Expenses: 2022170000.00
NATCAPSUQ.NS income_statement (quarterly, 2026-03-31) — Total Expenses: 614038000.00
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Total Liabilities Net Minority Interest: 1894357000.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 1894357000.00
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Total Non Current Assets: 2873575000.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 2873575000.00
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 567055000.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 567055000.00
NATCAPSUQ.NS income_statement (annual, 2026-03-31) — Total Other Finance Cost: 6744000.00
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Total Tax Payable: 14245000.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Total Tax Payable: 14245000.00
NATCAPSUQ.NS income_statement (annual, 2026-03-31) — Total Unusual Items: -5905000.00
NATCAPSUQ.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items: 0.00
NATCAPSUQ.NS income_statement (annual, 2026-03-31) — Total Unusual Items Excluding Goodwill: -5905000.00
NATCAPSUQ.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: 0.00
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Treasury Shares Number: 0.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Treasury Shares Number: 0.00
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Work In Process: 23751000.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Work In Process: 23751000.00
NATCAPSUQ.NS balance_sheet (annual, 2026-03-31) — Working Capital: 40701000.00
NATCAPSUQ.NS balance_sheet (quarterly, 2026-03-31) — Working Capital: 40701000.00
NATCAPSUQ.NS income_statement (annual, 2026-03-31) — Write Off: 5905000.00
NATCOPHARM.NS balance_sheet (annual, 2022-03-31) — Accumulated Depreciation: -7940000000.00
NATCOPHARM.NS balance_sheet (annual, 2022-03-31) — Additional Paid In Capital: 14089000000.00
NATCOPHARM.NS balance_sheet (annual, 2022-03-31) — Allowance For Doubtful Accounts Receivable: -422000000.00
NATCOPHARM.NS cash_flow (annual, 2022-03-31) — Amortization Cash Flow: 48000000.00
NATCOPHARM.NS income_statement (annual, 2022-03-31) — Basic Average Shares: 182372169.00
NATCOPHARM.NS income_statement (annual, 2022-03-31) — Basic EPS: 9.32
NATCOPHARM.NS balance_sheet (annual, 2022-03-31) — Buildings And Improvements: 9734000000.00
NATCOPHARM.NS balance_sheet (annual, 2022-03-31) — Cash Financial: 1111000000.00
NATCOPHARM.NS cash_flow (annual, 2022-03-31) — Common Stock Dividend Paid: -822000000.00
NATCOPHARM.NS cash_flow (annual, 2022-03-31) — Common Stock Payments: 0.00
NATCOPHARM.NS income_statement (annual, 2022-03-31) — Diluted Average Shares: 182409089.00
NATCOPHARM.NS income_statement (annual, 2022-03-31) — Diluted EPS: 9.32
NATCOPHARM.NS balance_sheet (annual, 2022-03-31) — Dividends Payable: 37000000.00
NATCOPHARM.NS balance_sheet (annual, 2022-03-31) — Finished Goods: 2129000000.00
NATCOPHARM.NS income_statement (annual, 2022-03-31) — General And Administrative Expense: 818000000.00
NATCOPHARM.NS balance_sheet (annual, 2022-03-31) — Gross Accounts Receivable: 6628000000.00
NATCOPHARM.NS balance_sheet (annual, 2022-03-31) — Hedging Assets Current: 10000000.00
NATCOPHARM.NS balance_sheet (annual, 2022-03-31) — Held To Maturity Securities: 583000000.00
NATCOPHARM.NS income_statement (annual, 2022-03-31) — Interest Income: 390000000.00
NATCOPHARM.NS income_statement (annual, 2022-03-31) — Interest Income Non Operating: 390000000.00
NATCOPHARM.NS balance_sheet (annual, 2022-03-31) — Land And Improvements: 2641000000.00
NATCOPHARM.NS balance_sheet (annual, 2022-03-31) — Machinery Furniture Equipment: 16798000000.00
NATCOPHARM.NS cash_flow (annual, 2022-03-31) — Net Business Purchase And Sale: -1031000000.00
NATCOPHARM.NS cash_flow (annual, 2022-03-31) — Net Other Financing Charges: -18000000.00
NATCOPHARM.NS balance_sheet (annual, 2022-03-31) — Non Current Deferred Revenue: 13000000.00
NATCOPHARM.NS balance_sheet (annual, 2022-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 957000000.00
NATCOPHARM.NS balance_sheet (annual, 2022-03-31) — Non Current Prepaid Assets: 151000000.00
NATCOPHARM.NS balance_sheet (annual, 2022-03-31) — Other Inventories: 328000000.00
NATCOPHARM.NS balance_sheet (annual, 2022-03-31) — Other Payable: 313000000.00
NATCOPHARM.NS income_statement (annual, 2022-03-31) — Other Special Charges: -427000000.00
NATCOPHARM.NS balance_sheet (annual, 2022-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 170000000.00
NATCOPHARM.NS balance_sheet (annual, 2022-03-31) — Prepaid Assets: 2746000000.00
NATCOPHARM.NS balance_sheet (annual, 2022-03-31) — Properties: 0.00
NATCOPHARM.NS cash_flow (annual, 2022-03-31) — Purchase Of Business: -1031000000.00
NATCOPHARM.NS balance_sheet (annual, 2022-03-31) — Raw Materials: 3413000000.00
NATCOPHARM.NS income_statement (annual, 2022-03-31) — Rent And Landing Fees: 32000000.00
NATCOPHARM.NS income_statement (annual, 2022-03-31) — Rent Expense Supplemental: 32000000.00
NATCOPHARM.NS cash_flow (annual, 2022-03-31) — Repurchase Of Capital Stock: 0.00
NATCOPHARM.NS income_statement (annual, 2022-03-31) — Research And Development: 1769000000.00
NATCOPHARM.NS balance_sheet (annual, 2022-03-31) — Restricted Cash: 37000000.00
NATCOPHARM.NS balance_sheet (annual, 2022-03-31) — Retained Earnings: 26666000000.00
NATCOPHARM.NS income_statement (annual, 2022-03-31) — Selling And Marketing Expense: 437000000.00
NATCOPHARM.NS income_statement (annual, 2022-03-31) — Selling General And Administration: 1255000000.00
NATCOPHARM.NS income_statement (annual, 2022-03-31) — Special Income Charges: 228000000.00
NATCOPHARM.NS cash_flow (annual, 2022-03-31) — Stock Based Compensation: 22000000.00
NATCOPHARM.NS income_statement (annual, 2022-03-31) — Total Other Finance Cost: 45000000.00
NATCOPHARM.NS income_statement (annual, 2022-03-31) — Total Unusual Items: 240000000.00
NATCOPHARM.NS income_statement (annual, 2022-03-31) — Total Unusual Items Excluding Goodwill: 240000000.00
NATCOPHARM.NS balance_sheet (annual, 2022-03-31) — Work In Process: 1750000000.00
NATCOPHARM.NS income_statement (annual, 2022-03-31) — Write Off: 199000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — +Operating Expense: 11613000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — +Total Revenue: 26969000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Accounts Payable: 2638000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Accounts Receivable: 8561000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Accumulated Depreciation: -9123000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Additional Paid In Capital: 14076000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Allowance For Doubtful Accounts Receivable: -150000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Amortization Cash Flow: 145000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Available For Sale Securities: 359000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Basic Average Shares: 182552365.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Basic EPS: 39.18
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Beginning Cash Position: 1111000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Buildings And Improvements: 10593000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Capital Expenditure: -2056000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Capital Lease Obligations: 17000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Capital Stock: 365000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Cash And Cash Equivalents: 1319000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Cash Cash Equivalents And Short Term Investments: 11248000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Cash Dividends Paid: -1004000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Cash Equivalents: 0.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Cash Financial: 1319000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Change In Inventory: 191000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Change In Other Current Assets: 689000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Change In Other Current Liabilities: 1027000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Change In Payable: 1020000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Change In Receivables: -2221000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Change In Working Capital: 627000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Changes In Cash: 90000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Common Stock: 365000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Common Stock Dividend Paid: -1004000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Common Stock Equity: 48738000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Common Stock Issuance: 0.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Common Stock Payments: -74000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Construction In Progress: 912000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Cost Of Revenue: 7455000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Current Assets: 30003000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Current Capital Lease Obligation: 6000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Current Debt: 1744000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Current Debt And Capital Lease Obligation: 1750000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Current Liabilities: 6831000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Current Provisions: 169000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Depreciation: 1493000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Depreciation And Amortization: 1638000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Depreciation And Amortization In Income Statement: 1638000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Depreciation Income Statement: 1638000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Diluted Average Shares: 182552365.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Diluted EPS: 39.18
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Diluted NI Availto Com Stockholders: 7153000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Dividends Payable: 37000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Dividends Received Cfi: 1000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — EBIT: 8714000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — EBITDA: 10352000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Effect Of Exchange Rate Changes: 118000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — End Cash Position: 1319000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Financing Cash Flow: -3630000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Finished Goods: 2866000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Free Cash Flow: 6435000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Gain Loss On Investment Securities: 51000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Gain Loss On Sale Of PPE: -178000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — General And Administrative Expense: 1069000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Goodwill: 552000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Goodwill And Other Intangible Assets: 1878000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Gross Accounts Receivable: 8711000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Gross PPE: 32426000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Gross Profit: 19514000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Hedging Assets Current: 0.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Held To Maturity Securities: 514000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Interest Expense: 95000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Interest Expense Non Operating: 95000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Interest Income: 512000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Interest Income Non Operating: 512000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Interest Paid Cff: -142000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Interest Received Cfi: 488000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Inventory: 7429000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Invested Capital: 50482000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Investing Cash Flow: -4771000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Investmentin Financial Assets: 873000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Issuance Of Capital Stock: 0.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Land And Improvements: 2855000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Long Term Capital Lease Obligation: 11000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Long Term Debt And Capital Lease Obligation: 11000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Long Term Provisions: 853000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Machinery Furniture Equipment: 17616000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Minority Interest: 0.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Minority Interests: 0.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Net Business Purchase And Sale: 0.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Net Common Stock Issuance: -74000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Net Debt: 425000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Net Foreign Currency Exchange Gain Loss: 0.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Net Income: 7153000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Net Income Common Stockholders: 7153000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Net Income Continuous Operations: 7153000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Net Income From Continuing And Discontinued Operation: 7153000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Net Income From Continuing Operation Net Minority Interest: 7153000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Net Income From Continuing Operations: 8619000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Net Income Including Noncontrolling Interests: 7153000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Net Intangibles Purchase And Sale: -593000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Net Interest Income: 367000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Net Investment Purchase And Sale: -4275000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Net Issuance Payments Of Debt: -2390000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Net Non Operating Interest Income Expense: 367000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Net Other Investing Changes: 766000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Net PPE: 23303000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Net PPE Purchase And Sale: -1158000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Net Short Term Debt Issuance: -2390000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Net Tangible Assets: 46860000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Revenue: 17000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Taxes Assets: 0.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Taxes Liabilities: 124000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 853000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Non Current Prepaid Assets: 170000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Normalized EBITDA: 10357000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Normalized Income: 7157149553.31
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Operating Cash Flow: 8491000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Operating Income: 7901000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Operating Revenue: 26969000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Ordinary Shares Number: 182470115.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Other Current Assets: 2290000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Other Current Liabilities: 546000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Other Equity Interest: 48373000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Other Intangible Assets: 1326000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Other Inventories: 306000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Other Non Cash Items: -383000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Other Non Current Assets: 271000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Other Non Current Liabilities: -42636000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Other Non Operating Income Expenses: 141000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Other Operating Expenses: 2226000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Other Payable: 337000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Other Properties: 450000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Other Receivables: 453000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Other Short Term Investments: 9929000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Other Special Charges: -178000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Otherunder Preferred Stock Dividend: 0.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Payables: 3113000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 169000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Prepaid Assets: 2265000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Pretax Income: 8619000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Properties: 0.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Provisionand Write Offof Assets: -239000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Purchase Of Business: 0.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Purchase Of Intangibles: -593000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Purchase Of Investment: -5363000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Purchase Of PPE: -1463000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Raw Materials: 2964000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Reconciled Cost Of Revenue: 7455000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Reconciled Depreciation: 1638000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Rent And Landing Fees: 49000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Rent Expense Supplemental: 49000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Repurchase Of Capital Stock: -74000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Research And Development: 902000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Restricted Cash: 47000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Retained Earnings: 32923000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Sale Of Investment: 1088000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Sale Of PPE: 305000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Selling And Marketing Expense: 961000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Selling General And Administration: 2030000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Share Issued: 182557165.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Special Income Charges: 47000000.00
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Stock Based Compensation: 0.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Stockholders Equity: 48738000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Tangible Book Value: 46860000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Tax Effect Of Unusual Items: -850446.69
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Tax Provision: 1466000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Tax Rate For Calcs: 0.17
NATCOPHARM.NS cash_flow (annual, 2023-03-31) — Taxes Refund Paid: -1775000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Total Assets: 56574000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Total Capitalization: 48738000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Total Debt: 1761000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Total Equity Gross Minority Interest: 48738000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Total Expenses: 19068000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Total Liabilities Net Minority Interest: 7836000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Total Non Current Assets: 26571000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Total Non Current Liabilities Net Minority Interest: 1005000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Total Other Finance Cost: 50000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Total Tax Payable: 101000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Total Unusual Items: -5000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Total Unusual Items Excluding Goodwill: -5000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Treasury Shares Number: 87050.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Work In Process: 1293000000.00
NATCOPHARM.NS balance_sheet (annual, 2023-03-31) — Working Capital: 23172000000.00
NATCOPHARM.NS income_statement (annual, 2023-03-31) — Write Off: 131000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — +Operating Expense: 15395000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — +Total Revenue: 39788000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Accounts Payable: 2355000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Accounts Receivable: 11889000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Accumulated Depreciation: -10638000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Additional Paid In Capital: 12037000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Allowance For Doubtful Accounts Receivable: -197000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Amortization Cash Flow: 161000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Available For Sale Securities: 959000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Basic Average Shares: 179495611.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Basic EPS: 77.34
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Beginning Cash Position: 1319000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Buildings And Improvements: 11080000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Capital Expenditure: -3587000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Capital Lease Obligations: 80000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Capital Stock: 358000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Cash And Cash Equivalents: 704000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Cash Cash Equivalents And Short Term Investments: 17760000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Cash Dividends Paid: -1708000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Cash Equivalents: 63000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Cash Financial: 641000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Change In Inventory: 424000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Change In Other Current Assets: -636000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Change In Other Current Liabilities: 116000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Change In Payable: -281000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Change In Receivables: -3413000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Change In Working Capital: -3094000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Changes In Cash: -680000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Common Stock: 358000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Common Stock Dividend Paid: -1708000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Common Stock Equity: 58531000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Common Stock Issuance: 0.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Common Stock Payments: -2537000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Construction In Progress: 2063000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Cost Of Revenue: 8625000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Current Assets: 40235000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Current Capital Lease Obligation: 27000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Current Debt: 3632000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Current Debt And Capital Lease Obligation: 3659000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Current Liabilities: 9728000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Current Provisions: 1029000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Depreciation: 1707000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Depreciation And Amortization: 1868000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Depreciation And Amortization In Income Statement: 1868000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Depreciation Income Statement: 1868000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Diluted Average Shares: 179495611.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Diluted EPS: 77.34
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Diluted NI Availto Com Stockholders: 13883000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Dividends Payable: 31000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Dividends Received Cfi: 3000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — EBIT: 16855000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — EBITDA: 18723000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Effect Of Exchange Rate Changes: 65000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — End Cash Position: 704000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Financing Cash Flow: -2469000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Finished Goods: 2731000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Free Cash Flow: 8529000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Gain Loss On Investment Securities: 4000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Gain Loss On Sale Of PPE: 17000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — General And Administrative Expense: 1153000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Goodwill: 560000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Goodwill And Other Intangible Assets: 1931000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Gross Accounts Receivable: 12086000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Gross PPE: 35678000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Gross Profit: 31163000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Held To Maturity Securities: 588000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Impairment Of Capital Assets: 0.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Interest Expense: 120000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Interest Expense Non Operating: 120000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Interest Income: 1010000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Interest Income Non Operating: 1010000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Interest Paid Cff: -181000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Interest Received Cfi: 585000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Inventory: 7005000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Invested Capital: 62163000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Investing Cash Flow: -10327000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Investmentin Financial Assets: 959000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Issuance Of Capital Stock: 0.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Land And Improvements: 3692000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Long Term Capital Lease Obligation: 53000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Long Term Debt And Capital Lease Obligation: 53000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Long Term Provisions: 709000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Machinery Furniture Equipment: 18340000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Minority Interest: 0.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Minority Interests: 0.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Net Common Stock Issuance: -2537000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Net Debt: 2928000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Net Foreign Currency Exchange Gain Loss: -8000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Net Income: 13883000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Net Income Common Stockholders: 13883000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Net Income Continuous Operations: 13883000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Net Income From Continuing And Discontinued Operation: 13883000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Net Income From Continuing Operation Net Minority Interest: 13883000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Net Income From Continuing Operations: 16735000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Net Income Including Noncontrolling Interests: 13883000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Net Intangibles Purchase And Sale: -193000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Net Interest Income: 818000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Net Investment Purchase And Sale: -6035000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Net Issuance Payments Of Debt: 1978000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Net Non Operating Interest Income Expense: 818000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Net Other Investing Changes: -1325000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Net PPE: 25040000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Net PPE Purchase And Sale: -3374000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Net Short Term Debt Issuance: 1978000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Net Tangible Assets: 56600000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Revenue: 40000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Assets: 194000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Liabilities: 2000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 709000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Non Current Prepaid Assets: 429000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Normalized EBITDA: 18798000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Normalized Income: 13945218404.54
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Operating Cash Flow: 12116000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Operating Income: 15768000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Operating Revenue: 39988000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Ordinary Shares Number: 179109870.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Other Current Assets: 2759000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Other Current Liabilities: 488000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Other Equity Interest: 58173000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Other Intangible Assets: 1371000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Other Inventories: 430000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Other Non Cash Items: -821000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Other Non Current Assets: 694000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Other Non Operating Income Expenses: 118000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Other Operating Expenses: 4316000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Other Payable: 477000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Other Properties: 503000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Other Receivables: 796000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Other Short Term Investments: 17056000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Other Special Charges: 17000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Otherunder Preferred Stock Dividend: 0.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Payables: 3186000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 1029000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Prepaid Assets: 2733000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Pretax Income: 16735000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Properties: 0.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Provisionand Write Offof Assets: 227000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Purchase Of Intangibles: -193000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Purchase Of Investment: -11859000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Purchase Of PPE: -3394000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Raw Materials: 2821000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Reconciled Cost Of Revenue: 8625000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Reconciled Depreciation: 1868000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Rent And Landing Fees: 59000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Rent Expense Supplemental: 59000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Repurchase Of Capital Stock: -2537000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Research And Development: 1417000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Restricted Cash: 52000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Retained Earnings: 44657000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Sale Of Intangibles: 0.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Sale Of Investment: 5824000000.00
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Sale Of PPE: 20000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Selling And Marketing Expense: 1530000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Selling General And Administration: 2683000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Share Issued: 179109870.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Special Income Charges: -68000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Stockholders Equity: 58531000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Tangible Book Value: 56600000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Tax Effect Of Unusual Items: -12781595.46
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Tax Provision: 2852000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Tax Rate For Calcs: 0.17
NATCOPHARM.NS cash_flow (annual, 2024-03-31) — Taxes Refund Paid: -2863000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Total Assets: 69063000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Total Capitalization: 58531000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Total Debt: 3712000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Total Equity Gross Minority Interest: 58531000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Total Expenses: 24020000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Total Liabilities Net Minority Interest: 10532000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Total Non Current Assets: 28828000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Total Non Current Liabilities Net Minority Interest: 804000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Total Other Finance Cost: 72000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Total Tax Payable: 323000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Total Unusual Items: -75000000.00
NATCOPHARM.NS income_statement (annual, 2024-03-31) — Total Unusual Items Excluding Goodwill: -75000000.00
NATCOPHARM.NS balance_sheet (annual, 2024-03-31) — Work In Process: 1023000000.00